41120-23-4

Basic information

• Product Name: ethyl 2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-1-carboxylate
• Synonyms: ethyl 2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-1-carboxylate;2,3-dihydro-2-oxo-1H-Benzimidazole-1-carboxylic acid ethyl ester;ethyl 2-oxo-3H-benzimidazole-1-carboxylate
• CAS NO: 41120-23-4
• Molecular Formula: C₁₀H₁₀N₂O₃
• Molecular Weight: 206.198
• Mol File: 41120-23-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.319g/cm³
• Refractive Index: 1.577
• CAS DataBase Reference: ethyl 2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-1-carboxylate(41120-23-4)
• EPA Substance Registry System: ethyl 2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-1-carboxylate(41120-23-4)

Safety Data

• Hazardous Substances Data: 41120-23-4(Hazardous Substances Data)

Usage

General Description

Ethyl 2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-1-carboxylate is a chemical compound with a molecular formula of C11H11NO3. It belongs to the class of organic compounds known as benzimidazoles, which are heterocyclic compounds containing a benzene ring fused to an imidazole ring. ethyl 2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-1-carboxylate is often used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and other bioactive compounds. It has potential applications in the development of new drugs, particularly in the treatment of various diseases and conditions. Ethyl 2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-1-carboxylate is a versatile compound that has attracted attention from researchers and chemists for its synthetic utility and potential biological activities.

InChI:InChI=1/C10H10N2O3/c1-2-15-10(14)12-8-6-4-3-5-7(8)11-9(12)13/h3-6H,2H2,1H3,(H,11,13)

Upstream product

• 615-16-7 1,3-dihydro-2H-benzimidazol-2-one 
• 7325-39-5 ethyl pyridine-2-yl carbonate 
• 161468-57-1 2-oxo-benzoimidazole-1,3-dicarboxylic acid diethyl ester 
• 615-16-7 1H-benzimidazol-2-ol 
• 506-68-3 bromocyane 
• 18631-99-7 N-hydroxy-N-phenyl-carbamic acid ethyl ester 

Downstream Products

• 339013-51-3 3-(2,6-dichloro-benzyl)-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester 
• 161921-87-5 1-(4-tert-butyldimethylsilyloxy-3-propylphenylmethyl)-3-carboethoxy-2-benzimidazolinone 
• 64928-98-9 1-(2-oxo-propyl)-1,3-dihydro-benzoimidazol-2-one 
• 30770-12-8 1-benzyl-5-bromo-1,3-dihydro-benzoimidazol-2-one 
• 396725-94-3 3-Benzyl-5-bromo-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid tert-butyl ester 
• 1026498-98-5 3-Benzyl-5-chloro-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid tert-butyl ester 
• 1027927-15-6 3-Benzyl-6-iodo-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester 
• 161468-78-6 3-Benzyl-6-bromo-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester 
• 161468-77-5 3-Benzyl-6-chloro-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester 
• 161468-89-9 5-Chloro-3-cyclohexylmethyl-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid tert-butyl ester 
• 1027285-95-5 5-Bromo-3-cyclohexylmethyl-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid tert-butyl ester 
• 161468-88-8 6-Chloro-3-cyclohexylmethyl-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester 
• 161469-06-3 1-Benzyl-6-bromo-1,3-dihydro-benzoimidazole-2-one 

Relevant articles and documents

Rational Design, Pharmacomodulation, and Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT7)/5-Hydroxytryptamine 2A (5-HT2A) Receptor Antagonists and Evaluation by [18F]-PET Imaging in a Primate Brain

We report the synthesis of 46 tertiary amine-bearing N-alkylated benzo[d]imidazol-2(3H)-ones, imidazo[4,5-b]pyridin-2(3H)-ones, imidazo[4,5-c]pyridin-2(3H)-ones, benzo[d]oxazol-2(3H)-ones, oxazolo[4,5-b]pyridin-2(3H)-ones and N,N′-dialkylated benzo[d]imidazol-2(3H)-ones. These compounds were evaluated against 5-HT7R, 5-HT2AR, 5-HT1AR, and 5-HT6R as potent dual 5-HT7/5-HT2A serotonin receptors ligands. A thorough study of the structure-activity relationship of the aromatic rings and their substituents, the alkyl chain length and the tertiary amine was conducted. 1-(4-(4-(4-Fluorobenzoyl)piperidin-1-yl)butyl)-1H-benzo[d]imidazol-2(3H)-one (79) and 1-(6-(4-(4-fluorobenzoyl)piperidin-1-yl)hexyl)-1H-benzo[d]imidazol-2(3H)-one (81) were identified as full antagonist ligands on cyclic adenosine monophosphate (cAMP, KB = 4.9 and 5.9 nM, respectively) and inositol monophosphate (IP1, KB = 0.6 and 16 nM, respectively) signaling pathways of 5-HT7R and 5-HT2AR. Both antagonists crossed the blood-brain barrier as evaluated with [18F] radiolabeled compounds [18F]79 and [18F]81 in a primate's central nervous system using positron emission tomography. Both radioligands showed standard uptake values ranging from 0.8 to 1.1, a good plasmatic stability, and a distribution consistent with 5-HT7R and 5-HT2AR in the CNS.

BENZIMIDAZOLINONES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES

Phenoxyphenylacetic acids and derivatives of the general structural formula I STR1 have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, pulmonary hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, inflammatory diseases including Raynaud's disease and asthma.

A NOVEL SYNTHESIS OF BENZIMIDAZOLINONES

A new route to N-monosubstituted benzimidazolinones, involving an hetero-oxy Cope rearrangement, consists in the reaction of hydroxamic acids with cyanogen bromide.